Immunotherapy News and Research

Latest Immunotherapy News and Research

Modified herpes virus improves survival in melanoma patients

University of Louisville researcher Jason Chesney, M.D., Ph.D., deputy director of the James Graham Brown Cancer Center, and a team of international scientists found that stage IIIb to IV melanoma patients treated with a modified cold sore (herpes) virus had improved survival.

30 May 2015

MD Anderson Cancer Center's Jim Allison to receive Science of Oncology Award at ASCO 2015

The world's leading organization of oncologists will honor Jim Allison, Ph.D., for his pioneering research that led to a new way to treat cancer by unleashing an immune system attack rather than targeting tumors directly.

30 May 2015

Pembrolizumab (Keytruda) effective in patients with recurrent or metastatic head and neck cancer

Immunotherapy with the anti-PD-1 antibody pembrolizumab (Keytruda) was effective in one out of four patients with recurrent or metastatic head and neck cancer, according to results presented at the 2015 meeting of the American Society for Clinical Oncology.

30 May 2015

Roche’s immunotherapy MPDL3280A better than chemotherapy in improving overall survival in NSCLC patients

Data to be presented at the 51st Annual Meeting of the American Society of Clinical Oncology suggest that the investigational immunotherapy MPDL3280A may double the likelihood of overall survival in the study period (HR=0.47), compared with docetaxel chemotherapy, in individuals with non-small cell lung cancer (NSCLC) who expressed the highest levels of PD-L1 (a receptor present on cancer cells).

30 May 2015

TxCell to deliver two presentations on Col-Treg and Ovasave at ISCT Annual Meeting

TxCell SA, a biotechnology company developing innovative, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that Dr. Arnaud Foussat, VP Research and New Products, TxCell, will deliver two presentations at the 21st Annual Meeting of the International Society of Cellular Therapy, May 27-30, 2015, in Las Vegas, Nevada, US.

30 May 2015

PDS Biotechnology announces positive results from PDS0101 Phase I trial in pre-cervical cancer patients

PDS Biotechnology Corp. announces preliminary data showing that PDS0101, a cancer immunotherapy treatment targeting HPV-16, has generated strong T-cell responses in pre-cervical cancer patients.

28 May 2015

TxCell reports results from annual general meeting of shareholders

28 May 2015

Amgen to present clinical data on multiple blood cancer treatments at EHA 2015

Amgen today announced that it will present data from multiple Kyprolis (carfilzomib) for Injection, BLINCYTO (blinatumomab), oprozomib and Nplate (romiplostim)‎ studies at the 20th Congress of the European Hematology Association taking place in Vienna, June 11 - 14, 2015.

28 May 2015

Genocea reports positive results from GEN-003 Phase 2 clinical trial for treatment of genital herpes

Genocea Biosciences, Inc., a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced positive top-line data from a Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes.

21 May 2015

Research shows how immune system controls biological clock in times of inflammation, infection

Researchers at Trinity College Dublin and the University of Pennsylvania have uncovered an important link between our body clock and the immune system that will have relevance to the treatment of inflammatory and infectious diseases.

20 May 2015

BioNTech, Genmab to jointly develop and commercialize immunomodulatory antibodies for cancer

BioNTech AG, a fully integrated biotechnology company developing truly personalized cancer immunotherapies, announces that it has signed an agreement with Genmab A/S to jointly research, develop and commercialize multiple bispecific antibodies for cancer immunotherapy using proprietary technologies from both companies: BioNTech's proprietary immunomodulatory antibodies and Genmab's DuoBody technology platform.

19 May 2015

Asthma Ally app allows patients to connect with allergist's office for assistance

The adage, "There's an app for that" is even more true in light of an app that sends an alert to your allergist's office when your asthma may be out of control.

15 May 2015

Immunotherapy for kidney cancer - Phase 3 update from Argos Therapeutics at ASCO

Argos is developing AGS-003, which is a fully personalized immunotherapy designed to induce a durable memory T-cell response specific to each patient’s cancer...

14 May 2015

Regulatory T cells can cure inflammatory diseases, shows research

Scientists at The University of Manchester have made an important discovery about an immune cell which is already being used in immunotherapy to treat diseases such as type I diabetes.

14 May 2015

Researchers devise novel method to perform NIR optical measurements of resected breast tissue

Roughly 1 in 4 women having breast conserving surgery (BCS) return to the surgical suite for further resection because of cancerous tissue left behind due to unclear margins. Investigators at the Optics in Medicine Lab at Dartmouth's Thayer School of Engineering and Norris Cotton Cancer Center, led by Brian W. Pogue, PhD and Keith Paulsen PhD, with first author and PhD candidate David M. McClatchy III, devised a novel approach to perform near infrared (NIR) optical measurements of resected breast tissue after the margins have had their traditional marking by the surgeon to preserve information about their orientation for potential follow-up surgeries.

14 May 2015

Research paves way for development of individualized immunotherapy for treating cancer

Mainz-based researchers have made significant advances with regard to the development of individualized immunotherapy strategies for treating cancer. They have managed to identify the relevant genetic changes or mutations associated with various types of cancer and have determined their individual blueprints.

13 May 2015

Invectys begins INVAC-1 phase I clinical trial in cancer patients

Invectys announces today that it has initiated a phase I clinical trial of its immunotherapeutic drug candidate INVAC-1.

13 May 2015

European Investment Bank supports Bavarian Nordic’s development of Ebola and cancer vaccines

The European Investment Bank (EIB), the world’s largest multilateral bank, today reaffirmed its firm commitment to respond to the Ebola pandemic. The Bank has provided a EUR 50 million loan to Bavarian Nordic, an international biopharmaceutical company, for accelerated development of an Ebola vaccine with long-term efficacy. The financing is also backing research into vaccines for treating other infectious diseases and multiple cancer indications.

12 May 2015

Study: Disrupting cancer pathway could extend benefits of new immunity-boosting drugs

Understanding how to overrule a signaling pathway that can cause treatments to fail in metastatic melanoma patients should help physicians extend the benefits of recently approved immunity-boosting drugs known as checkpoint inhibitors to more patients.

12 May 2015

Dana-Farber/Boston Children's joins immunotherapy clinical trial for children with ALL

Dana-Farber/Boston Children's Cancer and Blood Disorders Center has joined a clinical trial of immunotherapy for children with relapsed or treatment-resistant acute lymphoblastic leukemia (ALL). Led by Memorial Sloan Kettering Cancer Center, the trial is one of several nationally that are evaluating cancer immunotherapy, a treatment approach -- hailed by Science magazine as their Breakthrough of the Year in 2013 -- that triggers a patient's immune system to attack his or her cancer cells.

11 May 2015

Immunotherapy News and Research

Latest Immunotherapy News and Research

Modified herpes virus improves survival in melanoma patients

MD Anderson Cancer Center's Jim Allison to receive Science of Oncology Award at ASCO 2015

Pembrolizumab (Keytruda) effective in patients with recurrent or metastatic head and neck cancer

Roche’s immunotherapy MPDL3280A better than chemotherapy in improving overall survival in NSCLC patients

TxCell to deliver two presentations on Col-Treg and Ovasave at ISCT Annual Meeting

PDS Biotechnology announces positive results from PDS0101 Phase I trial in pre-cervical cancer patients

TxCell reports results from annual general meeting of shareholders

Amgen to present clinical data on multiple blood cancer treatments at EHA 2015

Genocea reports positive results from GEN-003 Phase 2 clinical trial for treatment of genital herpes

Research shows how immune system controls biological clock in times of inflammation, infection

BioNTech, Genmab to jointly develop and commercialize immunomodulatory antibodies for cancer

Asthma Ally app allows patients to connect with allergist's office for assistance

Immunotherapy for kidney cancer - Phase 3 update from Argos Therapeutics at ASCO

Regulatory T cells can cure inflammatory diseases, shows research

Researchers devise novel method to perform NIR optical measurements of resected breast tissue

Research paves way for development of individualized immunotherapy for treating cancer

Invectys begins INVAC-1 phase I clinical trial in cancer patients

European Investment Bank supports Bavarian Nordic’s development of Ebola and cancer vaccines

Study: Disrupting cancer pathway could extend benefits of new immunity-boosting drugs

Dana-Farber/Boston Children's joins immunotherapy clinical trial for children with ALL

Exploring Strategies for Targeting Kinases in Innate Immunity eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Immunotherapy News and Research

Latest Immunotherapy News and Research

Exploring Strategies for Targeting Kinases in Innate Immunity eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in